A model combining clinical and genomic factors to predict response to PD-1/PD-L1 blockade in advanced urothelial carcinoma

[1]  P. Therasse.  Immune-Related Response Criteria , 2020, Definitions.

[2]  E. V. Van Allen,et al.  Mutational Analysis of 472 Urothelial Carcinoma Across Grades and Anatomic Sites , 2018, Clinical Cancer Research.

[3]  S. M. Vareki.  High and low mutational burden tumors versus immunologically hot and cold tumors and response to immune checkpoint inhibitors , 2018 .

[4]  Qiang Li,et al.  ERCC2 Helicase Domain Mutations Confer Nucleotide Excision Repair Deficiency and Drive Cisplatin Sensitivity in Muscle-Invasive Bladder Cancer , 2018, Clinical Cancer Research.

[5]  P. Hegde,et al.  Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial , 2018, The Lancet.

[6]  M. Berger,et al.  Alterations in DNA Damage Response and Repair Genes as Potential Marker of Clinical Benefit From PD-1/PD-L1 Blockade in Advanced Urothelial Cancers. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  P. Hegde,et al.  Atezolizumab (atezo) vs. chemotherapy (chemo) in platinum-treated locally advanced or metastatic urothelial carcinoma (mUC): Immune biomarkers, tumor mutational burden (TMB), and clinical outcomes from the phase III IMvigor211 study. , 2018 .

[8]  G. Pond,et al.  New 6-factor prognostic model for patients (pts) with advanced urothelial carcinoma (UC) receiving post-platinum atezolizumab. , 2018 .

[9]  R. Bourgon,et al.  TGF-β attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells , 2018, Nature.

[10]  Ahmet Zehir,et al.  Molecular Determinants of Response to Anti-Programmed Cell Death (PD)-1 and Anti-Programmed Death-Ligand 1 (PD-L1) Blockade in Patients With Non-Small-Cell Lung Cancer Profiled With Targeted Next-Generation Sequencing. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  Feng Xu,et al.  Unwrapping the genomic characteristics of urothelial bladder cancer and successes with immune checkpoint blockade therapy , 2018, Oncogenesis.

[12]  M. Delgado-Rodríguez,et al.  Systematic review and meta-analysis. , 2017, Medicina intensiva.

[13]  P. Ascierto,et al.  Baseline neutrophils and derived neutrophil-to-lymphocyte ratio: prognostic relevance in metastatic melanoma patients receiving ipilimumab. , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[14]  N. Socci,et al.  Accelerating Discovery of Functional Mutant Alleles in Cancer. , 2018, Cancer discovery.

[15]  N. Schultz,et al.  NEXT GENERATION SEQUENCING OF NON‐MUSCLE INVASIVE BLADDER CANCER REVEALS POTENTIAL BIOMARKERS AND RATIONAL THERAPEUTIC TARGETS: PD48‐11 , 2017, European urology.

[16]  J. Rosenberg,et al.  Atezolizumab in platinum-treated locally advanced or metastatic urothelial carcinoma: post-progression outcomes from the phase II IMvigor210 study , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

[17]  M. Ringnér,et al.  Mutational and putative neoantigen load predict clinical benefit of adoptive T cell therapy in melanoma , 2017, Nature Communications.

[18]  Tae Min Kim,et al.  Genomic landscape associated with potential response to anti-CTLA-4 treatment in cancers , 2017, Nature Communications.

[19]  Steven J. M. Jones,et al.  Comprehensive Molecular Characterization of Muscle-Invasive Bladder Cancer , 2017, Cell.

[20]  Ludmila V. Danilova,et al.  Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade , 2017, Science.

[21]  D. Bajorin,et al.  Pembrolizumab for Advanced Urothelial Carcinoma. , 2017, The New England journal of medicine.

[22]  Moriah H Nissan,et al.  OncoKB: A Precision Oncology Knowledge Base. , 2017, JCO precision oncology.

[23]  H. Khong,et al.  Neutrophil-to-lymphocyte ratio as prognostic indicator in gastrointestinal cancers: a systematic review and meta-analysis , 2017, Oncotarget.

[24]  L. Macconaill,et al.  Validation of OncoPanel: A Targeted Next-Generation Sequencing Assay for the Detection of Somatic Variants in Cancer. , 2017, Archives of pathology & laboratory medicine.

[25]  P. A. Futreal,et al.  Integrated molecular analysis of tumor biopsies on sequential CTLA-4 and PD-1 blockade reveals markers of response and resistance , 2017, Science Translational Medicine.

[26]  S. Culine,et al.  Pembrolizumab as Second‐Line Therapy for Advanced Urothelial Carcinoma , 2017, The New England journal of medicine.

[27]  M. Berger,et al.  DNA Damage Response and Repair Gene Alterations Are Associated with Improved Survival in Patients with Platinum-Treated Advanced Urothelial Carcinoma , 2017, Clinical Cancer Research.

[28]  J. Sosman,et al.  Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma , 2017, Cell.

[29]  S. Elledge,et al.  Tumor aneuploidy correlates with markers of immune evasion and with reduced response to immunotherapy , 2017, Science.

[30]  Mingming Jia,et al.  COSMIC: somatic cancer genetics at high-resolution , 2016, Nucleic Acids Res..

[31]  M. Atkins,et al.  Predictive biomarkers for checkpoint inhibitor-based immunotherapy. , 2016, The Lancet. Oncology.

[32]  Marian Harris,et al.  Institutional implementation of clinical tumor profiling on an unselected cancer population. , 2016, JCI insight.

[33]  T. Curiel,et al.  Safety and Efficacy of Durvalumab (MEDI4736), an Anti-Programmed Cell Death Ligand-1 Immune Checkpoint Inhibitor, in Patients With Advanced Urothelial Bladder Cancer. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[34]  J. Lunceford,et al.  Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial. , 2016, The Lancet. Oncology.

[35]  R. Bourgon,et al.  Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial , 2016, The Lancet.

[36]  P. Ascierto,et al.  Baseline neutrophils and derived neutrophil-to-lymphocyte ratio: prognostic relevance in metastatic melanoma patients receiving ipilimumab. , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

[37]  Nicolai J. Birkbak,et al.  Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade , 2016, Science.

[38]  Birgit Funke,et al.  VisCap: inference and visualization of germ-line copy-number variants from targeted clinical sequencing data , 2015, Genetics in Medicine.

[39]  James Y. Zou.  Analysis of protein-coding genetic variation in 60,706 humans , 2015, Nature.

[40]  Lai Wei,et al.  Peritumoural neutrophils negatively regulate adaptive immunity via the PD-L1/PD-1 signalling pathway in hepatocellular carcinoma , 2015, Journal of Experimental & Clinical Cancer Research.

[41]  A. Ravaud,et al.  Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. , 2015, The New England journal of medicine.

[42]  D. Jayne,et al.  Systemic neutrophil-to-lymphocyte ratio in colorectal cancer: the relationship to patient survival, tumour biology and local lymphocytic response to tumour , 2015, British Journal of Cancer.

[43]  Bert Vogelstein,et al.  PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. , 2015, The New England journal of medicine.

[44]  B. Vogelstein,et al.  PD-1 blockade in tumors with mismatch repair deficiency. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[45]  T. Choueiri,et al.  KEYNOTE-045: Randomized phase 3 trial of pembrolizumab (MK-3475) versus paclitaxel, docetaxel, or vinflunine for previously treated metastatic urothelial cancer. , 2015 .

[46]  Martin L. Miller,et al.  Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer , 2015, Science.

[47]  K. Koike,et al.  PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. , 2015, The New England journal of medicine.

[48]  Maya Petersen,et al.  Computationally efficient confidence intervals for cross-validated area under the ROC curve estimates. , 2015, Electronic journal of statistics.

[49]  Maxim N. Artyomov,et al.  Checkpoint Blockade Cancer Immunotherapy Targets Tumour-Specific Mutant Antigens , 2014, Nature.

[50]  J. Taube,et al.  Association of PD-1, PD-1 Ligands, and Other Features of the Tumor Immune Microenvironment with Response to Anti–PD-1 Therapy , 2014, Clinical Cancer Research.

[51]  David T. W. Jones,et al.  Signatures of mutational processes in human cancer , 2013, Nature.

[52]  Kristian Rother,et al.  REPAIRtoire—a database of DNA repair pathways , 2010, Nucleic Acids Res..

[53]  P. Bork,et al.  A method and server for predicting damaging missense mutations , 2010, Nature Methods.

[54]  Axel Hoos,et al.  Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria , 2009, Clinical Cancer Research.

[55]  S. Henikoff,et al.  Predicting the effects of coding non-synonymous variants on protein function using the SIFT algorithm , 2009, Nature Protocols.

[56]  Valérie Ferreira,et al.  VEGF release by MMP-9 mediated heparan sulphate cleavage induces colorectal cancer angiogenesis. , 2008, European journal of cancer.

[57]  H. Zou.  The Adaptive Lasso and Its Oracle Properties , 2006 .

[58]  Roel P F Schins,et al.  Neutrophils and respiratory tract DNA damage and mutagenesis: a review. , 2006, Mutagenesis.

[59]  Alberto Mantovani,et al.  Inflammation and cancer: back to Virchow? , 2001, The Lancet.

[60]  Frank E. Harrell,et al.  Regression Modeling Strategies: With Applications to Linear Models, Logistic Regression, and Survival Analysis , 2001 .

[61]  G M Clark,et al.  Prediction of relapse or survival in patients with node-negative breast cancer by DNA flow cytometry. , 1989, The New England journal of medicine.

[62]  O. Kallioniemi,et al.  Prognostic significance of dna index, multiploidy, and S‐phase fraction in ovarian cancer , 1988, Cancer.

[63]  R. C. Macridis.  A review , 1963 .